ALR Technologies Inc. Release: Clinical Trial Follow-up Confirms Discontinuation of Intensive Blood Glucose Control Results in Reversal of A1c Improvement

ATLANTA, GA--(Marketwire - July 28, 2011) - ALR Technologies Inc. (OTCBB: ALRT) announces follow-up results of a clinical trial with diabetes patients has been published in the Canadian Journal of Diabetes, July 2011 issue. The trial was headed by Dr. Hugh Tildesley, a leading endocrinologist in Canada, and the paper can be viewed at: http://www.diabetes.ca/documents/for-professionals/CJD--July_2011--H.Tildesley_.pdf

Dr. Tildesley conducted a 12 month study using the ALRT Health-e-Connect (HeC) System as an Internet Based Blood Glucose Monitoring System (IBGMS) to provide intensive blood glucose control to determine the effects internet based blood glucose monitoring on A1c levels in patients with type 2 diabetes treated with insulin.

Fifty patients were randomly assigned to receive conventional care (Control Group) or conventional care with additional follow-up via IBGMS (IBGMS Group) for 6 months. The IBGMS Group uploaded blood glucose readings to a secure website and received feedback from their endocrinologist on a regular basis. After 6 months, all patients returned to conventional care. A1c data were collected at 0, 3, 6 and 12 months.

At the 6-month follow-up, A1c of the IBGMS Group dropped from 8.8% to 7.6% compared to the Control Group, which showed no significant change 8.5% to 8.4%. At the end of 6 months, both groups continued with routine care without internet intervention. A1c values were compared at 12 months, the A1c differences between the IBGMS Group and Control Group were not sustained; 8.2% for the IBGMS Group compared to 8.5% for the Control Group.

Dr. Tildesley concluded that, “While IBGMS intervention was not a substitute for the patient-physician interaction in a clinical setting, it significantly improved A1c and, over time, we observed better glycemic control and patient satisfaction. This method of follow-up can reduce the inconvenience of booking appointments solely for giving recommendations on changes in insulin dosage and may be a more cost-effective method of follow-up, especially for rural patients where access to a diabetes specialist is limited. In summary, the continuous use of an IBGMS is an effective method of improving glucose control compared to standard care.”

Dr. Tildesley added, “The advantages of using an IBGMS include automatic uploading thus eliminating the need for patients to keep a written diary. In addition, the uploaded data can be analyzed and displayed in table and graph formats, giving a sense of glucose trends and monitoring frequency. This can save time for the physician and increase the accuracy of data interpretation.

“Limitations of the system include patient’s unwillingness or lack of desire to use the Internet and the absence of a payment model to reimburse out-of-office consultations.”

About ALR Technologies Inc.
ALRT Health-e-Connect (HeC) System is the principal product of the Company. HeC is a web based patient management platform for medical professionals to improve compliance and adherence of care plans of patients in their homes. HeC is programmed to assist healthcare providers caring for diabetes patients. The platform will be expanded to cover patients with other chronic diseases. The HeC System is not available for sale in the US pending FDA 510(k) clearance. More information on ALR Technologies and its products can be found at http://www.alrt.com.

This release contains certain “forward-looking statements” relating to ALR Technologies’ business, and these statements reflect the current views of ALR Technologies with respect to future events and are subject to certain risks, uncertainties and assumptions. When used, the words “estimate”, “expect”, “anticipate”, “believe” and similar expressions are intended to identify such forward-looking statements. There are many factors that could cause the actual results, performance or achievements of ALR Technologies and its products to be materially different from any future results, performances or achievements that may be expressed or implied by such forward-looking statements. Further management discussions of risks and uncertainties can be found in the company’s quarterly filings with the Securities Exchange Commission.